Cargando…

Genome-wide analysis toward the epigenetic aetiology of myelodysplastic syndrome disease progression and pharmacoepigenomic basis of hypomethylating agents drug treatment response

Myelodysplastic syndromes (MDS) consist of a group of hematological malignancies characterized by ineffective hematopoiesis, cytogenetic abnormalities, and often a high risk of transformation to acute myeloid leukemia (AML). So far, there have been only a very limited number of studies assessing the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Siamoglou, Stavroula, Boers, Ruben, Koromina, Maria, Boers, Joachim, Tsironi, Anna, Chatzilygeroudi, Theodora, Lazaris, Vasileios, Verigou, Evgenia, Kourakli, Alexandra, van IJcken, Wilfred F. J., Gribnau, Joost, Symeonidis, Argiris, Patrinos, George P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10127336/ https://www.ncbi.nlm.nih.gov/pubmed/37098643 http://dx.doi.org/10.1186/s40246-023-00483-7

Ejemplares similares

Allogeneic Hematopoietic Stem Cell Transplantation for Mixed or Overlap Myelodysplastic/Myeloproliferative Disorders
por: Symeonidis, Argiris, et al.
Publicado: (2022)

Contingent Synergistic Interactions between Non-Coding RNAs and DNA-Modifying Enzymes in Myelodysplastic Syndromes
por: Symeonidis, Argiris, et al.
Publicado: (2022)

High Frequency of Post-Transfusion Microchimerism Among Multi-Transfused Beta-Thalassemic Patients
por: Matsagos, Spyridon, et al.
Publicado: (2022)

Genome-wide DNA methylation profiling using the methylation-dependent restriction enzyme LpnPI
por: Boers, Ruben, et al.
Publicado: (2018)

Genome wide DNA methylation analysis of alveolar capillary dysplasia lung tissue reveals aberrant methylation of genes involved in development including the FOXF1 locus
por: Slot, Evelien, et al.
Publicado: (2021)

Impact of ZBTB7A hypomethylation and expression patterns on treatment response to hydroxyurea
por: Chondrou, Vasiliki, et al.
Publicado: (2018)

Pharmacoepigenomic Interventions as Novel Potential Treatments for Alzheimer’s and Parkinson’s Diseases
por: Teijido, Oscar, et al.
Publicado: (2018)

Common cardiovascular biomarkers can independently predict outcome of patients with Myelodysplastic syndromes
por: Mitroulis, Ioannis, et al.
Publicado: (2023)

The pharmacoepigenomic landscape of cancer cell lines reveals the epigenetic component of drug sensitivity
por: Ohnmacht, Alexander Joschua, et al.
Publicado: (2023)

Genome-wide aberrant methylation in primary metastatic UM and their matched metastases
por: Smit, Kyra N., et al.
Publicado: (2022)

Examining key factors impact on health science students’ intentions to adopt genetic and pharmacogenomics testing: a comparative path analysis in two different healthcare settings
por: Koufaki, Margarita-Ioanna, et al.
Publicado: (2022)

Whole transcriptome analysis of human erythropoietic cells during ontogenesis suggests a role of VEGFA gene as modulator of fetal hemoglobin and pharmacogenomic biomarker of treatment response to hydroxyurea in β-type hemoglobinopathy patients
por: Chondrou, Vasiliki, et al.
Publicado: (2017)

Bone Marrow Immune Microenvironment in Myelodysplastic Syndromes
por: Kouroukli, Olga, et al.
Publicado: (2022)

Differentially Methylated Regions in Desmoid-Type Fibromatosis: A Comparison Between CTNNB1 S45F and T41A Tumors
por: Timbergen, Milea J. M., et al.
Publicado: (2020)

Retrospective analysis of enhancer activity and transcriptome history
por: Boers, Ruben, et al.
Publicado: (2023)

Chronic Neutrophilic Leukemia: A Comprehensive Review of Clinical Characteristics, Genetic Landscape and Management
por: Thomopoulos, Thomas P., et al.
Publicado: (2022)

The Lipoprotein Transport System in the Pathogenesis of Multiple Myeloma: Advances and Challenges
por: Lazaris, Vasileios, et al.
Publicado: (2021)

Azacytidine Failure Revisited: an Appraisal Based on Real-Life Data from the MDS Registry of the Hellenic Myelodysplastic Syndrome Study Group (HMDS)
por: Kotsianidis, Ioannis, et al.
Publicado: (2019)

Genetic and epigenetic determinants of reactivation of Mecp2 and the inactive X chromosome in neural stem cells
por: Mira-Bontenbal, H., et al.
Publicado: (2022)

Real world data on the prognostic significance of monocytopenia in myelodysplastic syndrome
por: Diamantopoulos, Panagiotis T., et al.
Publicado: (2022)

Management of myelodysplastic syndromes after failure of response to hypomethylating agents
por: Gil-Perez, Angela, et al.
Publicado: (2019)

The incidence of myelodysplastic syndromes in Western Greece is increasing
por: Avgerinou, Christina, et al.
Publicado: (2013)

MicroRNA expression and DNA methylation profiles do not distinguish between primary and recurrent well-differentiated liposarcoma
por: Vos, Melissa, et al.
Publicado: (2020)

Liquid Biopsies for Colorectal Cancer and Advanced Adenoma Screening and Surveillance: What to Measure?
por: Eikenboom, Ellis L., et al.
Publicado: (2023)

A Novel Text-Mining Approach for Retrieving Pharmacogenomics Associations From the Literature
por: Pandi, Maria-Theodora, et al.
Publicado: (2020)

Somatic mutations predict outcomes of hypomethylating therapy in patients with myelodysplastic syndrome
por: Jung, Seung-Hyun, et al.
Publicado: (2016)

Oral Hypomethylating Agents for Myelodysplastic Syndromes: Highlights From SOHO 2020
Publicado: (2021)

A machine learning model of response to hypomethylating agents in myelodysplastic syndromes
por: Radakovich, Nathan, et al.
Publicado: (2022)

Risk factors for cardiovascular disease mortality in patients with myelodysplastic syndromes: A nationwide, registry‐based cohort study
por: Liapis, Konstantinos, et al.
Publicado: (2020)

Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms
por: Montalban-Bravo, Guillermo, et al.
Publicado: (2018)

Rapid in vitro generation of bona fide exhausted CD8+ T cells is accompanied by Tcf7 promotor methylation
por: Zhao, Manzhi, et al.
Publicado: (2020)

Exome-Wide Analysis of the DiscovEHR Cohort Reveals Novel Candidate Pharmacogenomic Variants for Clinical Pharmacogenomics
por: Pandi, Maria-Theodora, et al.
Publicado: (2020)

Hypermethylation of DNA Methylation Markers in Non-Cirrhotic Hepatocellular Carcinoma
por: Fu, Siyu, et al.
Publicado: (2023)

Delineating significant genome-wide associations of variants with antipsychotic and antidepressant treatment response: implications for clinical pharmacogenomics
por: Koromina, Maria, et al.
Publicado: (2020)

Refinement of prognosis and the effect of azacitidine in intermediate-risk myelodysplastic syndromes
por: Liapis, Konstantinos, et al.
Publicado: (2021)

Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents
por: Takahashi, Koichi, et al.
Publicado: (2016)

No benefit of hypomethylating agents compared to supportive care for higher risk myelodysplastic syndrome
por: Sohn, Sang Kyun, et al.
Publicado: (2018)

Arsenic Disulfide Promoted Hypomethylation by Increasing DNA Methyltransferases Expression in Myelodysplastic Syndrome
por: Zhou, Qing-Bing, et al.
Publicado: (2020)

Hypomethylating Agents and Immunotherapy: Therapeutic Synergism in Acute Myeloid Leukemia and Myelodysplastic Syndromes
por: Wong, Kah Keng, et al.
Publicado: (2021)

Hypomethylating Chemotherapeutic Agents as Therapy for Myelodysplastic Syndromes and Prevention of Acute Myeloid Leukemia
por: Sorrentino, Vincent G., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8rpd96fhnqv0s22o46f0hcda8p